Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 210 Main Street West BAUDETTE MN 56623 |
Tel: | 1-212-4522793 |
Website: | https://www.anipharmaceuticals.com |
IR: | See website |
Key People | ||
Nikhil Suresh Lalwani President, Chief Executive Officer, Director | Stephen P. Carey Chief Financial Officer, Senior Vice President | Krista Davis Chief Human Resource Officer |
Meredith Cook Senior Vice President, General Counsel, Company Secretary | Chad Gassert Senior Vice President - Corporate Development and Strategy | Ori Gutwerg Senior Vice President - Generics |
James G. Marken Senior Vice President - Operations | Christopher K. Mutz Senior Vice President, Head of Rare Diseases | Muthusamy Shanmugam Director, Head of Research and Development, Chief Operating Officer - Novitium Operations |
Business Overview |
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers. |
Financial Overview |
For the fiscal year ended 31 December 2023, ANI Pharmaceuticals Inc revenues increased 54% to $486.8M. Net income applicable to common stockholders totaled $15.5M vs. loss of $49.5M. Revenues reflect Generics Established Brands and Other segment increase of 36% to $374.7M, Rare Disease segment increase from $41.7M to $112.1M. Net Income reflects Restructuring activities decrease of 80% to $1.1M (expense). |
Employees: | 642 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,465M as of Dec 31, 2023 |
Annual revenue (TTM): | $486.82M as of Dec 31, 2023 |
EBITDA (TTM): | $107.89M as of Dec 31, 2023 |
Net annual income (TTM): | $15.48M as of Dec 31, 2023 |
Free cash flow (TTM): | $108.47M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $64.55M as of Dec 31, 2023 |
Shares outstanding: | 20,991,171 as of Mar 27, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |